CDK9-IN-7
|
|
|
- CAS号:
- 2369981-71-3
- 英文名:
- CDK9-IN-7
- 英文别名:
- CDK9-IN-7;CDK9-IN-7, 10 mM in DMSO;CDK-9-IN-7,CDK9IN7,CDK9 IN 7;7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 7-cyclopentyl-2-[[4-[(8-isothiocyanato-1-oxooctyl)amino]phenyl]amino]-N,N-dimethyl-
- 中文名:
- CDK9-IN-7
- 中文别名:
- 化合物 T10745;化合物CDK9-IN-7;化合物CDK9-IN-7,10 MM DMSO 溶液
- CBNumber:
- CB85821208
- 分子式:
- C29H37N7O2S
- 分子量:
- 547.71
- MOL File:
- 2369981-71-3.mol
|
|
|
CDK9-IN-7化学性质
-
密度:
-
1.26±0.1 g/cm3(Predicted)
-
|
-
酸度系数(pKa):
-
14.60±0.70(Predicted)
-
|
-
形态:
-
Solid
-
|
-
颜色:
-
Light yellow to yellow
-
|
CDK9-IN-7性质、用途与生产工艺
CDK9-IN-7 (compound 21e) 是一种高效选择性的，具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM)，与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡，在 G2 期阻滞细胞周期，并具有抑制非小细胞肺癌干细胞特性。
|
CDK9/cyclinT1
11 nM (IC
50
)
|
CDK4/cyclin D
148 nM (IC
50
)
|
CDK6/cyclinD
145 nM (IC
50
)
|
CDK9-IN-7 displays exceptional potency against NSCLC cell lines, especial A549 and H1299 with IC
50
values less than 0.5 µM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency with an IC
50
value of 0.837 µM.
CDK9-IN-7
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2025/02/08 | HY-126251 | CDK9-IN-7
CDK9-IN-7 | 2369981-71-3 | 25 mg | 7413元 |
| 2025/02/08 | HY-126251 | CDK9-IN-7
CDK9-IN-7 | 2369981-71-3 | 10 mM * 1 mLin DMSO | 8154元 |
2369981-71-3, CDK9-IN-7 相关搜索:
- 抑制剂
- C29H37N7O2S
- 化合物CDK9-IN-7,10 MM DMSO 溶液
- 化合物CDK9-IN-7
- 化合物 T10745
- 2369981-71-3
- CDK9-IN-7, 10 mM in DMSO
- CDK-9-IN-7,CDK9IN7,CDK9 IN 7
- 7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 7-cyclopentyl-2-[[4-[(8-isothiocyanato-1-oxooctyl)amino]phenyl]amino]-N,N-dimethyl-
- CDK9-IN-7